Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Inherited Metabolic Disease
Metadata
Title
Holocarboxylase synthetase deficiency: Urinary metabolites masked by gross ketosis
Authors
K. H. Carpenter
B. Wilcken
J. Christodoulou
D. R. Thorburn
Publication date
01-12-2000
Publisher
Kluwer Academic Publishers
Published in
Journal of Inherited Metabolic Disease / Issue 8/2000
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1023/A:1026721021233

Other articles of this Issue 8/2000

Journal of Inherited Metabolic Disease 8/2000 Go to the issue

ReviewPaper

Trifunctional protein deficiency: Three families with significant maternal hepatic dysfunction in pregnancy not associated with E474Q mutation

ReviewPaper

Ornithine carbamoyltransferase deficiency presenting with chorea in a female

ReviewPaper

Prolactin, a marker for cerebral dopamine deficiency in patients suffering from phenylketonuria (PKU)?

ReviewPaper

A novel mitochondrial transfer RNA proline mutation

ReviewPaper

Plasma creatinine assessment in creatine deficiency: A diagnostic pitfall

BookReview

James F. Crow, William F. Dove (Editors), Perspectives on GENETICS: Anecdotal, historical and critical commentaries – 1987–1998

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits